- Home
- LAKE vs PLX Comparison
LAKE vs PLX Comparison
Compare LAKE & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAKE
- PLX
- Stock Information
- Founded
- LAKE 1982
- PLX 1993
- Country
- LAKE United States
- PLX Israel
- Employees
- LAKE N/A
- PLX N/A
- Industry
- LAKE Industrial Specialties
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LAKE Health Care
- PLX Health Care
- Exchange
- LAKE Nasdaq
- PLX Nasdaq
- Market Cap
- LAKE 192.4M
- PLX 160.2M
- IPO Year
- LAKE 1986
- PLX 1998
- Fundamental
- Price
- LAKE $20.63
- PLX $2.59
- Analyst Decision
- LAKE Strong Buy
- PLX Strong Buy
- Analyst Count
- LAKE 3
- PLX 1
- Target Price
- LAKE $27.67
- PLX $15.00
- AVG Volume (30 Days)
- LAKE 93.6K
- PLX 764.3K
- Earning Date
- LAKE 04-09-2025
- PLX 03-17-2025
- Dividend Yield
- LAKE 0.61%
- PLX N/A
- EPS Growth
- LAKE N/A
- PLX N/A
- EPS
- LAKE N/A
- PLX 0.04
- Revenue
- LAKE $151,822,000.00
- PLX $53,399,000.00
- Revenue This Year
- LAKE $37.18
- PLX $67.17
- Revenue Next Year
- LAKE $22.27
- PLX $55.31
- P/E Ratio
- LAKE N/A
- PLX $71.07
- Revenue Growth
- LAKE 23.99
- PLX N/A
- 52 Week Low
- LAKE $15.10
- PLX $0.82
- 52 Week High
- LAKE $27.28
- PLX $2.76
- Technical
- Relative Strength Index (RSI)
- LAKE 48.20
- PLX 58.97
- Support Level
- LAKE $19.65
- PLX $2.43
- Resistance Level
- LAKE $20.83
- PLX $2.62
- Average True Range (ATR)
- LAKE 0.95
- PLX 0.14
- MACD
- LAKE 0.19
- PLX 0.02
- Stochastic Oscillator
- LAKE 78.29
- PLX 85.00
About LAKE Lakeland Industries Inc.
Lakeland Industries Inc manufactures and sells safety garments and accessories for the industrial protective clothing market. Its product segments include Disposables, Chemicals, Fire, Gloves, High Visibility, High-Performance Wear, and Wovens. Its customers include integrated oil, chemical/petrochemical, utilities, automobile, steel, glass, construction, smelting, munition plants, janitorial, pharmaceutical, and mortuaries, as well as scientific and medical laboratories. Its geographical segments include the United States, Latin America, Canada, Asia, Mexico, Europe (United Kingdom), and Other Foreign.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.